Induced pluripotent stem cells (iPSCs) provide a potential source for the derivation of smooth muscle cells (SMCs); however, current approaches are limited by the production of heterogeneous cell types and a paucity of tools or markers for tracking and purifying candidate SMCs. Here, we develop murine and human iPSC lines carrying fluorochrome reporters (Acta2 hrGFP and ACTA2 
INTRODUCTION
Smooth muscle cells (SMCs) function to regulate the tone of blood vessels, airways, and intestines within the body, and SMC dysfunction is characteristic of prevalent diseases, including atherosclerosis (Bennett et al., 2016) and asthma (Pelaia et al., 2008) . In either normal or diseased states, SMCs typically exist in defined layers, and emerging new engineering techniques present the possibility of generating layered tissue-like structures, such as vessel walls, including functional smooth muscle-like sheets to reconstitute normal function. Using autologous cells to engineer these sheets is a particularly compelling approach explored by some groups (Hibino et al., 2012; Kito et al., 2013; L'heureux et al., 1998; Syedain et al., 2011) , but harvesting an expandable source of smooth muscle progenitors from patients has been limited by the tendency of adult SMCs to lose their phenotype during cell culture (Alexander and Owens, 2012) .
Alternatively, induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006) , which self-renew indefinitely in vitro, are poised to be an inexhaustible source of autologous smooth muscle cells (iPSC-SMCs) for these engineered tissue constructs. Their efficacy and functionality, however, depends on the ability to generate pure populations of SMCs from iPSCs. While many protocols exist for producing iPSC-SMCs, to date, their differentiation in vitro results in heterogeneous populations (Maguire et al., 2017) , and there are no surface markers available for purification of live SMCs. Early differentiation protocols for producing SMCs from pluripotent stem cells (PSCs) use a single inductive medium recipe (Drab et al., 1997; Sinha et al., 2004) . Other protocols rely on forced overexpression of regulators of SMC gene expression, such as myocardin (Raphel et al., 2012; Yoshida et al., 2004) . Recognizing that SMCs are derived from multiple embryological lineages, such as neural crest and mesodermal lineages, several groups have more recently utilized developmental stagespecific approaches to pattern PSCs first toward neural crest, paraxial mesoderm, or lateral plate mesoderm before further specifying the cells toward an SMC lineage using serum-containing (Dash et al., 2016; Eoh et al., 2017; Ferreira et al., 2007; Lee et al., 2010; Marchand et al., 2014; Sinha et al., 2006; Syedain et al., 2011; Wang et al., 2012) or serum-free medium Yang et al., 2016) . For example, Wang et al. (2012) used iPSC-derived neural crest cells to generate a population enriched in smooth muscle lineages through treatment with serum and transforming growth factor b (TGF-b). Cheung et al. (2012) described serum-free differentiation of PSCs to smooth muscle-like cells through neuroectoderm, lateral plate mesoderm, and paraxial mesoderm intermediates. Still other groups have differentiated cells through a kinase insert domain receptor (KDR)-expressing mesodermal intermediate (Gadue et al., 2006; Nostro et al., 2008; Prasain et al., 2014) or a similar mesodermal intermediate (Patsch et al., 2015) into smooth muscle-like cells. These effective stage-specific in vitro approaches recapitulate milestones of SMC development in vivo in order to derive putative iPSC-SMCs in vitro. Although these studies produce a high percentage yield of SMCs scored by intracellular staining of fixed specimens, no methods have yet been 
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Pre GFP+ GFP- Here, we have engineered mouse and human iPSC lines, carrying fluorochrome reporters for Acta2 expression, to accomplish the live cell tracking and purification of candidate SMCs. We utilize these purified derivatives to characterize their global molecular and functional phenotypes in comparison with primary cells, and produce the first known engineered cell sheets from iPSC-derived putative SMCs.
We have selected the mouse Acta2 (or human ACTA2) locus for reporter targeting for our developmental system: Acta2 is one of the earliest characteristic markers of SMCs broadly expressed during embryonic development . Our results indicate that developmental differentiation of iPSCs via mesoderm in serum-free defined conditions produces Acta2 + /ACTA2 + cells expressing transcriptomic profiles reminiscent of immature or synthetic SMCs, with low levels of contractile SMC marker gene expression and functional capacity to form engineered cell sheets. In summary, we present a stem cell-based model system that recapitulates SMC development and produces highly characterized, purifiable SMC candidates for future regenerative medicine or tissue engineering applications.
RESULTS

Generation of miPSC-Derived Acta2 hrGFP+ Cells
To develop a method for derivation and purification of autologous candidate SMCs from iPSCs, we focused first on generating a murine iPSC line (miPSC) whose phenotype could be compared with in vivo SMCs of the same genetic background. A transgenic mouse expressing humanized Renilla reniformis green fluorescent protein (hrGFP) following a rat Acta2 promoter sequence (Acta2 hrGFP ) (Figure 1A) exhibits GFP fluorescence selectively in embryonic and adult SMCs (Ghosh et al., 2011) . Hence, we reprogrammed tail tip fibroblasts from this mouse into iPSCs (Figures 1A and S1) using an excisable STEMCCA cassette we have previously published (Sommer et al., 2009) . We employed the resulting miPSC line (hereafter Acta2 hrGFP ) to optimize a protocol ( Figure 1B ) for derivation of lateral plate mesodermal progenitors competent in forming candidate SMCs. In serum-free cultures, we tested varying doses and durations of bone morphogenetic protein 4 (BMP4), activin A, and Wnt3a ( Figure S2 ), given prior reports establishing the role of activin A and Wnt3a in primitive streak formation and BMP signaling in promoting posterior primitive streak differentiation into KDR + mesodermal progenitors (Gadue et al., 2006; Nostro et al., 2008) . We found that 3 ng/mL Wnt3a, 3 ng/mL BMP4, and 2 ng/mL activin A induced KDR + cells with an efficiency of 20% in our iPSC line, peaking on day 5 of differentiation ( Figure S3A ). The KDR + population at this time point was enriched for Foxf1, a lateral plate mesoderm marker. Meanwhile, Pax2 (intermediate mesoderm), Tbx6 (paraxial mesoderm), and Foxa2 (endoderm) were only expressed at low levels in the KDR + population ( Figure S3B ).
Next, to understand the competence of mesodermal precursors to differentiate toward a smooth muscle-like cell, we sorted KDR + and KDR À populations on day 5 and replated these cells in media containing previously published growth factors, platelet-derived growth factor BB (PDGF-BB), TGF-b, and fibroblast growth factor 2 (FGF2) (hereafter PT), known to promote generation of SMCs from iPSCs in vitro . While little GFP (<1%) fluorescence was noted in KDR + cells on day 5 ( Figure 1C ), GFP induction was easily detected in the outgrowth of KDR + sorted cells within 3 days after exposure to these factors, increasing to 31.9% ± 1.1% by day 13. Acta2 hrGFP+ cells were significantly enriched in the outgrowth of the KDR + replated population as compared with the KDR À population ( Figure 1C ), and differentiation efficiency was higher in defined (PT) serum-free conditions compared with previously published conditions that employ serum ( Figure 1C) , and absolute fold change, hereafter ''FC,'' >5) revealed ten gene clusters. As expected, these clusters contained gene signatures indicative of undifferentiated iPSCs (cluster 8), lateral plate mesoderm (cluster 6), immature/synthetic smooth muscle (clusters 5 and 7), and mature/contractile smooth muscle (cluster 1) ( Figure 2C and Table S1 ). For example, day-0 (or undifferentiated) mouse iPSCs expressed pluripotency markers such as Nanog, Zfp42, Klf5, Dppa4, and Dppa2. By day 5, iPSCs differentiated into KDR + mesodermal intermediates, significantly downregulated these markers ( Figure 2C ), and upregulated mesodermal-associated transcripts, Kdr, T (primitive streak), Foxf1 (lateral plate mesoderm), and Pdgfrb. Figure 1F) ; however, the Acta2 hrGFP+ population expressed significantly higher levels of Tagln and Pdgfrb as well as higher levels of other synthetic smooth muscle markers such as Myl9, Itgb5, Actg2, and Aebp1 (Table S1 ; FDR < 0.05). While contractile smooth muscle markers (Tpm2, Itga8, Ecm1, Cnn1, Smtn, and Myh11) were only expressed at low levels compared with aorta controls, the expression level of Tpm2 was enriched in Acta2 hrGFP+ compared with Acta2 hrGFPÀ cells.
Next, we chose two approaches to compare gene expression programs between engineered (iPSC-derived Acta2 hrGFP+ ) cells and primary aorta controls. First, we determined the number of differentially expressed genes (FDR < 0.05) between a common comparator (KDR + day-5 progenitors) versus the engineered or versus the primary cells. We found that the majority of genes were commonly upregulated or downregulated ( Figure 3A ) in engineered and primary cells. Focusing only on transcription factors (TFs), we similarly found the majority of TFs were differentially expressed (FDR < 0.05) in common in either engineered or primary cells compared with KDR + precursors ( Figure 3B ). Second, we sought to determine which signaling pathways were changing over time during the specification of our Acta2 hrGFP+ cells from their precursors and whether these changes were similar in primary aortic smooth muscle cell controls. Gene set enrichment analysis (GSEA) revealed that the top five enriched gene sets were upregulated in both engineered cells and controls. These five gene sets were ''epithelial mesenchymal transition,'' ''hypoxia,'' ''myogenesis,'' ''coagulation,'' and ''TNFA signaling via NFKB.'' In addition, both comparisons showed enrichment of ''angiogenesis'' and ''TGFbeta signaling'' gene sets ( Figure 3C ). When looking at the top enriched genes within the ''myogenesis'' gene set in the Acta2 hrGFP+ versus KDR + comparison, a majority of the genes (11/16) were also highly expressed in aortic SMCs, such as Col3a1, Aebp1, Tagln, and Myom1 ( Figure 3D , left). However, cardiomyocyte markers, Tnnt2 and Tnni1, were highly expressed in the in vitro Acta2 hrGFP+ cells, but lowly expressed in primary aortic SMCs. Because Acta2 is also known to be expressed in developing cardiomyocytes , this raised the possibility of cardiomyocytes present in the Acta2 hrGFP+ population. To quantify the presence of any contaminating cardiomyocytes, we used flow cytometry after staining for the cardiomyocyte marker, TNNT2, and found that 1.6% ± 0.6% of GFP + cells were TNNT2 + ( Figure S4 ). In contrast to our protocol, serum-containing protocols for SMC differentiation contained significantly higher numbers (4.6% ± 0.5% of See also Figure S4 and Table S1 .
controls. In top-ranked genes within the ''myogenesis'' gene set from the aortic SMC versus KDR + comparison using GSEA, we noted the expression of SMC contractile markers, such as Myh11 and Smtn, in aortic SMCs, but these markers were expressed at low levels in the iPSC-derived Acta2 hrGFP+ population ( Figure 3D , right Figure 3E) whereas myogenesis genes, such as Myh11 and Myocd, an SMC transcriptional co-activator, were both found in the top differentially expressed genes and TFs in primary aortic SMCs (GSEA based on 3,127 transcripts upregulated in aortic SMC and 4,444 downregulated in aortic SMC, FDR < 0.05).
Generation of Human iPSC-Derived ACTA2 eGFP+ Cells
Next, we sought to engineer putative SMCs from human iPSCs (hiPSCs) in vitro. The reporter mouse iPSC system allowed us to isolate a population of ACTA2 + cells enriched in putative SMCs; however, the transgenic reporter did not mark all ACTA2 + cells. To address this issue, we used CRISPR/Cas9 gene editing (Ran et al., 2013) to target an enhanced GFP reporter (eGFP) to the endogenous human ACTA2 locus in normal human iPSCs (BU3 [Kurmann et al., 2015] ; Figure 4A ). Because smooth muscle a actin functions in cell movement and contraction of SMCs, we chose a targeting strategy designed to allow for translation of both ACTA2 and the eGFP reporter by introducing a P2A-eGFP cassette in place of the endogenous ACTA2 stop codon. Two clones were identified with successful monoallelic and biallelic targeting of the ACTA2 locus (BU3 AG8Cr1 and BU3 AG18Cr1, respectively; Figure S5 ). To differentiate each iPSC clone, we followed similar developmental pathways and strategies as in our mouse system, focusing first on their differentiation into KDR + mesoderm using a published serum-free medium (Prasain et al., 2014) supplemented with BMP4, vascular endothelial growth factor (VEGF), FGF2, and activin A for 24 h, followed by 72 h with BMP4, VEGF, and FGF2 ( Figure 4B ). In contrast to mouse iPSCs, we observed some expression of GFP in undifferentiated human iPSCs ( Figure 4C Figure 5C ). Furthermore, MYOCD, a transcription co-activator of the SMC lineage, was found in the top ten upregulated TFs (FDR < 0.05) in the ACTA2 eGFP+ population ( Figure 5D ), and a variety of additional SMC markers were upregulated in the ACTA2 eGFP+ cells ( Figure 5E ; FDR<0.05). GSEA also revealed enrichment in gene sets similar to the GSEA of the mouse microarray, including ''myogenesis,'' ''TGFbeta signaling,'' and ''angiogenesis'' ( Figure 5F ). Notably, top enriched genes in the ''myogenesis'' gene set included TAGLN, TPM2, MYH9, COL1A1, and COL3A1 ( Figure 5G ).
Generation and Characterization of iPSC-SMC Cell Sheets
To determine whether our iPSC derivatives could serve as building blocks for engineered smooth muscle tissue constructs, we next utilized a micropatterned eGFP+ and ACTA2 eGFPÀ cells compared with freshly isolated uncultured primary human airway SMC controls. Error bars represent average ± SD. *p % 0.05 and **p % 0.01 by unpaired two-tailed Student's t test between GFP + and GFP À populations. n = 3 independent experiments. See also Figure S5 .
enzyme-degradable hydrogel system ( Figure 6A ) (Rim et al., 2018) to generate releasable aligned cell sheets that maintain cell-cell junctions and extracellular matrix (ECM) proteins. After seeding, sorted human or mouse iPSC-SMCs aligned in the direction of the micropatterns, consistent with our previously published work using multiple micropatterned substrate systems (Backman et al., 2017a; Rim et al., 2018) . Notably, the Acta2 hrGFP+ population retained Figure 6 . Generation of iPSC-SMC Cell Sheets (A) Schematic of alginate-tyramine hydrogel and cell sheet fabrication. Soft lithography techniques were used to fabricate micropatterned alginate-tyramine hydrogels to generate aligned cell sheets, and a hydrogel-specific enzyme was used to degrade the hydrogel and leave cell-cell junctions and ECM proteins intact. expression of the GFP reporter following alignment on the alginate scaffold ( Figure 6B ). Additionally, expression of many characteristic SMC markers (Acta2, Tagln, Myh10, Myh11, Col3a1) remained unchanged, but expression of Cnn1 was upregulated and expression of Col1a1 and Eln was downregulated in Acta2 hrGFP+ cells after cell sheet formation on alginate substrates ( Figure S6 ). Due to effects of tissue stiffness on SMC phenotype and detrimental effects of mechanical mismatch on engineered blood vessel patency (Salacinski et al., 2001 ), we were interested in characterizing mechanical properties of iPSC-derived cell sheets. Individual, single-layer cell sheets from mouse and human iPSC-derived cells as well as a control mouse aortic SMC line (MOVAS)-harvested after 4-6 weeks of culture on alginate substrates-underwent uniaxial tensile testing in the direction parallel to alignment to evaluate stress-strain responses ( Figure 6C ). As expected, cell sheets displayed non-linear mechanical behavior, although there was a minimal ''toe region,'' where the cell sheet undergoes strain while producing little stress. Furthermore, many samples underwent small breaks before complete failure, indicating multiple sites of failure, as shown by small decreases in stress around strains of 0.2 and 0.5. The stress-strain curves were analyzed to calculate elastic modulus, stress at failure (max stress), and strain at failure (max strain) ( Figures 6D-6F ). Mouse iPSC-derived Acta2 hrGFP+ cell sheets had significantly higher elastic modulus compared with the MOVAS control cell sheets but were not significantly different from that of Acta2 hrGFPÀ cell sheets. The moduli of the samples were in the 50-to 250-kPa range, which is in the range of elastic moduli of bovine vascular SMC sheets previously reported by our group (Backman et al., 2017a; Rim et al., 2018) ; however, this range of moduli is on the lower end of reported stiffnesses for blood vessels and engineered vascular grafts (0.1-50 MPa) (Guo and Kassab, 2003; Lashkarinia et al., 2018; Wagenseil and Mecham, 2009 showed minimal change in surface area as a readout of contractility in response to agonists (carbachol and angiotensin II) (data not shown).
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As the markers used to define maturity and synthetic/ contractile phenotype of SMCs overlap, it is difficult to distinguish whether our in vitro derived cells are immature or synthetic compared with the mature and contractile primary SMC controls, but comparisons of the two populations suggests candidate pathways that might be harnessed to induce in vitro cells to become more like primary SMCs. Comparison of primary aortic SMCs and our in vitro Acta2 hrGFP+ cells using GSEA revealed multiple signaling pathways that are enriched in the primary aortic SMCs, including Notch signaling, which plays a role in SMC development and phenotype switching (Fouillade et al., 2012) . Modulation of these signaling pathways could enhance maturation or could induce phenotypic switching of the in vitro derived cells. Other studies have examined effects of biochemical and biomechanical cues on SMC phenotype switching and expression of contractile markers . Modulation of these cues can readily be explored to further enhance mature/contractile marker expression in our iPSC-derived cells. For example, a recent publication described a three-dimensional culture system for culturing and expanding iPSC-derived smooth muscle-like cells, which resulted in increased expression of contractile markers relative to the two-dimensional culture system (Lin et al., 2018b) . Other studies utilized pulsatile flow/ stretch bioreactors on engineered vascular grafts to modulate SMC phenotype (Niklason et al., 1999; Syedain et al., 2011) , which could be adopted to enhance the contractile phenotype of our iPSC-SMC cell sheets. Although previous publications of iPSC-SMCs described expression of contractile markers either through staining or transcriptomic data, in contrast to our work, most prior reports have not included comparisons with uncultured primary SMC controls. Given the rapid loss of SMC programs known to occur in most primary SMC culture systems (Weissberg et al., 1995) , it will be important in future studies to compare the contractile profile of cells with freshly isolated primary controls following modulation of these biochemical and biomechanical cues. Even though the iPSC-SMCs in this study may be more immature or synthetic in phenotype, it is important to note that synthetic SMCs play a role in inflammation, atherosclerosis, and vascular remodeling (Lim and Park, 2014) through proliferation, and secretion of ECM proteins or inflammatory cytokines. Thus, iPSC-SMCs may be useful in studying and treating vascular disorders such as atherosclerosis. The synthetic SMC phenotype also plays a major role during development and vasculogenesis, whereby the cells are highly migratory and proliferative while also secreting ECM proteins including collagen, elastin, proteoglycans, cadherins, and integrins . This more developmental synthetic phenotype could be beneficial in our in vitro system to generate cell sheets as building blocks for multi-layered SMC tissue constructs.
Despite advancements facilitated by access to purified iPSC-derived putative SMCs, many questions still remain, including how to adequately establish SMC identity in engineered cell types and specifically how to determine which subtype of SMC is being derived. Acta2/ACTA2 is not specific to SMCs, as it is also found in myofibroblasts and cardiomyocytes. Based on our flow-cytometry quantification of the cardiomyocyte marker, TNNT2, as well as microarray analysis, we found a low but detectable presence of potential cardiac lineage cells within our Acta2 hrGFP+ population. As Acta2 is not a specific marker, additional markers may need to be used to identify SMCs and completely exclude any potential cardiomyocyte presence. Recent work published by Sinha and colleagues had also begun to probe the effects of embryological origins on vascular SMC phenotype using an iPSC system in order to understand the role of those SMCs during disease. However, as with most prior reports, the potential presence of cardiomyocyte lineages, which can derive from some of these mesodermal intermediates, was not evaluated. There is also little literature investigating the differences between various SMC subtypes (e.g., vascular, airway), resulting in a paucity of markers to distinguish between those types. For example, to distinguish between vascular and airway SMCs, Notch3 (Ghosh et al., 2011) and Cspg4 (Paez-Cortez et al., 2013) have been previously reported as helpful markers of SMC subtypes, with the co-expression of CSPG4 and ACTA2 being restricted to arteries rather than veins (Murfee et al., 2005) . In this study, we have compared our iPSC-SMCs with either primary aortic or airway SMCs with regard to characteristic SMC markers (Acta2, Tagln, Myh11, Col1a1, and Eln), which have not been shown to be different between SMC subtypes. However, it will be important to identify distinct markers of primary SMC populations to better characterize iPSC-SMC identity.
In this study, we utilized micropatterned enzyme-degradable hydrogels (Rim et al., 2018) to generate aligned cell sheets from iPSC-derived GFP + cells, which can be used as building blocks to generate an engineered tissue construct composed of multiple aligned layers similar to the structure of blood vessels. Although many methods have now been described for generating cell sheets, including thermoresponsive, magnetic-based, and electroresponsive systems (Akintewe et al., 2017) , this enzyme-degradable hydrogel system allows for modulation of substrate stiffness, which can be used as a biomechanical cue to alter SMC phenotype (synthetic versus contractile, immature versus mature) in future studies. In our studies, we saw an upregulation of a more contractile marker, Cnn1, with a downregulation of ECM proteins, Col1a1 and Eln, after cell sheet formation, suggestive of a possible shift toward a more mature or contractile phenotype. Compared with typical arterial stressstrain, our iPSC-derived SMC cell sheets also displayed non-linear mechanical behavior, with a much less pronounced ''toe region,'' where strain produces minimal stress. This ''toe region'' is due to the untangling of ECM proteins as well as the difference in mechanical properties of collagen and elastin (Roach and Burton, 1957) . The small ''toe region'' could be due to a difference in ECM composition compared with that of the native blood vessel. The elastic moduli of the iPSC-derived cell sheets in this study were lower than in our previously reported work (Backman et al., 2017a; Rim et al., 2018) , which may be due to the lack of treatment with ascorbic acid, an additive used in previous studies. The moduli of the iPSC-derived cell sheets was also lower than the modulus of blood vessels (Guo and Kassab, 2003; Lashkarinia et al., 2018; Wagenseil and Mecham, 2009) ; however, blood vessels have a complex architectural structure composed of multiple aligned SMC layers oriented in different directions, while only single-layer cell sheets were tested in this study. Previous work from our group (Rim et al., 2018) explored mechanical properties of multi-layered bovine vascular SMC sheets; future work will need to focus on characterizing mechanical properties of stacked iPSCderived cell sheets. The blood vessel is also composed of multiple layers of ECM proteins such as collagen and elastin, so further characterization of ECM content and structure in iPSC-derived single-and multi-layered cell sheets is necessary. In addition, the max stress and max strain of the iPSC-derived cell sheets were also within physiologically relevant ranges, where blood vessels typically undergo~20% strain (Fung and Liu, 1992) and wall stresses of 75-150 kPa (Chuong and Fung, 1986; Koullias et al., 2005) . It is important to note that these studies described a distribution of stress and strains across the vessel wall, so it will be important to study the mechanical behavior of multi-layered iPSC-derived tissue constructs. A multi-layer cell sheet-based study characterized mechanical properties of fibroblast cell sheets rolled into multi-layered tubes with burst pressures of approximately 3,500 mmHg (Konig et al., 2009) , which calculates to approximately 2-3 MPa. In addition to characterizing the mechanical behavior at baseline, it will be important to study the mechanical behavior of these tissue constructs in the presence of SMC agonists and antagonists, such as nitric oxide, prostacyclin, endothelin, and angiotensin, which we did not characterize due to the sensitivity of tensile testers, which are capable of measuring forces in the mN-to-N force range (Backman et al., 2017b) . Cellular traction forces of SMCs have been reported in the 100-Pa range (Lin et al., 2018a) , which is roughly in the nN force range when accounting for the area of a cell. Future studies of the iPSC-SMC constructs in the presence of agonists and antagonists will need to be performed using tools, such as microscopy and micropillars (Polacheck and Chen, 2016) , for measuring cellular traction forces. In summary, we have purified mouse and human iPSCderived populations, which express characteristic SMC markers. Our transcriptomic profiling of these cells reveals a phenotype similar to immature or synthetic SMCs with low levels of contractile smooth muscle markers. In addition, the transcriptomic analysis highlights possible pathways and TFs enriched in primary SMCs as compared with iPSC-derived populations, providing hints as to biochemical cues that can be modulated to further mature iPSC-derived populations. Finally, we generated mouse and human iPSC-derived aligned cell sheets with elastic moduli, max stress, and max strains within physiological ranges to serve as building blocks for multi-layered smooth muscle tissue constructs.
EXPERIMENTAL PROCEDURES
For detailed experimental procedures regarding microarray profiling of iPSC-derived populations, GSEA analysis, immunostainings, qRT-PCR, and statistical methods, please refer to Supplemental Experimental Procedures.
Generation of Acta2
hrGFP Mouse iPSC and Knockin
ACTA2 eGFP Human iPSC Reporter Systems
All mouse studies including tissue harvests and iPSC derivation were approved by Boston University's Institutional Animal Care and Use Committee. An Acta2 hrGFP reporter mouse iPSC line was generated by reprogramming tail tip fibroblasts isolated from adult female C57BL/6 Acta2 hrGFP transgenic mice (Ghosh et al., 2011) .
The excisable lentiviral STEMCCA-loxP vector was employed as previously published (Sommer et al., 2009 ). In brief, following the completion of reprogramming, a single copy of the floxed STEMCCA-loxP vector was excised using transient expression of adenoviral Cre recombinase, and a normal female karyotype was documented by G-banding analysis (Cell Line Genetics, Madison, WI). Mouse iPSC lines were maintained on mouse embryonic fibroblasts in mouse embryonic stem cell medium for all experiments. All human iPSCs were generated with informed consent and approval of Boston University's Institutional Review Board. ACTA2 eGFP reporter lines were generated using the CRISPR/Cas9 system to target BU3 iPSCs, as detailed in Supplemental Experimental Procedures.
Directed Differentiation of Mouse iPSCs into Acta2 hrGFP+ Cells
Mouse iPSCs were differentiated through a mesodermal progenitor expressing KDR and then further specified toward a smooth muscle-like lineage by modifying previously reported methods (Gadue et al., 2006; Nostro et al., 2008) . In brief, 2 3 10 6 cells were plated in 10-cm non-adherent Petri dishes (Fisher), allowing embryoid bodies (EBs) to be formed during 48 h of leukemia inhibitory factor withdrawal in a complete serum-free differentiation medium (cSFDM) detailed in Supplemental Experimental Procedures. EBs were then treated with 2 ng/mL recombinant human (rh) activin A (R&D Systems, #338-AC), 3 ng/mL rhBMP4 (R&D Systems, #314-BP), and 3 ng/mL recombinant mouse (rm) Wnt3a (R&D Systems, #1324-WN-010) for 72 h to generate mesodermal progenitors and then plated without enzymatic digestion onto gelatincoated plates (~500,000 cells in a well of a 6-well plate) in cSFDM supplemented with 10 ng/mL rhPDGF-BB (Life Technologies, #PHG0046), 10 ng/mL rmTGF-b (R&D Systems, #7666-MB-005), and 10 ng/mL rhFGF2 (R&D Systems, #233-FB). On day 13 of differentiation, cells were dissociated and sorted by gating on viable (calcein blue + ) GFP-expressing cells. Where indicated in the text, day-5 cells were sorted on KDR after staining with APC rat antimouse KDR antibody (1:50 dilution, BD Biosciences, #560070).
Directed Differentiation of Human iPSCs into ACTA2
eGFP+ Cells
Human iPSCs were differentiated into mesoderm and then further specified toward a smooth muscle-like lineage based on previously described literature (Prasain et al., 2014) with the following modifications. In brief, hiPSCs were dissociated into single-cell suspensions using Gentle Cell Dissociation Reagent, and 500,000 cells were plated onto a fresh Matrigel-coated well of a 6-well plate (Corning) in mTeSR supplemented with 10 mM Y-27632 (Fisher Scientific, #1254/50) for 48 h prior to directed differentiation. Human iPSCs were then treated with Stemline II Hematopoietic Stem Cell Expansion medium (Sigma-Aldrich, #S0192) supplemented with 10 ng/mL each of rhBMP4 (R&D Systems, #314-BP), rhActivin A (R&D Systems, #338-AC), rhVEGF (Fisher Scientific, #293-VE), and rhFGF2 (R&D System, #233-FB) for 24 h, followed by 72 h of treatment with 10 ng/mL each of rhBMP4, rhVEGF, and rhFGF2 to generate mesoderm. Cells were then dissociated with Gentle Cell Dissociation Reagent at 37 C for 3 min and passaged in small clumps onto fresh Matrigel-coated plates in cSFDM supplemented with 10 ng/mL rhPDGF-BB (Life Technologies, #PHG0046), 10 ng/mL rhTGF-b (Fisher Scientific, #240-B-010), and 10 ng/mL rhFGF2 (R&D Systems, #233-FB). Cells were dissociated and sorted based on viability (calcein blue + ) and GFP expression for further analysis between days 20 and 30. Where indicated in the text, KDR expression was analyzed after staining with a PE mouse anti-human CD309 antibody (1:50 dilution, BD Biosciences, #560494).
Hydrogel Substrate and Cell Sheet Fabrication
Alginate-tyramine was synthesized as previously described (Rim et al., 2018) , described in detail in Supplemental Experimental Procedures. Alginate hydrogels were generated in micropatterned 10% gelatin molds (30 mm wide 3 30 mm spacing). Hydrogel substrates were coated using rat tail collagen type I before seeding with iPSC-SMCs or a control immortalized mouse aortic SMC line, MOVAS (ATCC, Manassas, VA). Cells were cultured using a common medium used for culturing primary SMCs, containing DMEM (Invitrogen, #11995-073), 10% fetal bovine serum (Fisher, #SH3007103), L-glutamine (final concentration 2 mM, Invitrogen, #25030-164), and primocin.
Mechanical Characterization of Cell Sheets
To characterize mechanical properties, we harvested cell sheets using 0.2 mg/mL alginate lyase (Sigma, A1603) and then utilized a custom-built uniaxial tensile tester, previously developed (Backman et al., 2017b) and described in further detail in Supplemental Experimental Procedures.
